Selbyville, Delaware, Sept. 10, 2023 (GLOBE NEWSWIRE) --
Sickle Cell Disease Treatment Market size is expected to be worth USD 7.79 billion by 2032. SCD is a genetic disorder that affects millions of people worldwide. The development of novel therapies, such as gene therapy, and the increasing focus on personalized medicine are revolutionizing the way SCD is treated.
Request for a sample of this research report @ https://www.gminsights.com/request-sample/detail/5697
Furthermore, the expansion of healthcare infrastructure in emerging economies and the growing support from governments and non-governmental organizations for SCD research and treatment offer promising prospects for industry development.
BMT to emerge as a key treatment modality for SCD
The sickle cell disease treatment market is divided into pharmacotherapy, blood transfusion, and bone marrow transplant. The bone marrow transplant segment will hold a commendable share of the sickle cell disease treatment industry by 2032. BMT is the only known cure for SCD, and its adoption has been increasing due to the growing number of successful transplant cases and advancements in transplant techniques. These include non-myeloablative conditioning regimens and other treatments which have increased the success rate and reduced complications. As a result, the demand for bone marrow transplants as a treatment modality for SCD is growing over the years.
Growing awareness of unique treatment requirements of HbSC
Sickle cell disease treatment market size from the hemoglobin sickle C disease (HbSC) segment will grow at a remarkable pace through 2032. HbSC is a milder form of SCD, characterized by less severe symptoms and complications. The growing awareness about HbSC and its unique treatment requirements has led to an increased demand for targeted therapies and specialized care.
Multidisciplinary treatment approach to drive demand for SCD therapies in specialty clinics
Sickle cell disease treatment market value from the specialty clinics segment will expand significantly over 2023-2032. These clinics provide specialized care for SCD patients, offering comprehensive treatment plans tailored to individual needs. They offer a multidisciplinary approach, including hematologists, genetic counselors, pain management specialists, and social workers, to ensure holistic care for SCD patients. The growing number of specialty clinics, coupled with the increasing awareness about the importance of specialized care for SCD patients.
Europe to remain a prominent growth hub for industry
Europe sickle cell disease treatment market size is set to record substantial revenue by 2032, driven by the growing prevalence of the disease among various ethnic groups and the widespread availability of advanced healthcare facilities. The European region has witnessed a significant rise in SCD prevalence in recent years, leading to higher demand for effective treatments, increased R&D investments, and growing support from governments and non-governmental organizations. Such developments are likely to bolster the regional market outlook over the forecast period.
Request for Report Customization @ https://www.gminsights.com/roc/5697
Sickle Cell Disease Treatment Industry Players
Major companies in the sickle cell disease treatment market include Novartis AG, Pfizer Inc., Medunik USA Inc., Emmaus Medical Inc., Bluebird Bio, Inc., CRISPR Therapeutics, Bristol-Myers Squibb Company, Agios Pharmaceuticals, Editas Medicine Inc., and Vifor Pharma.
Sickle Cell Disease Treatment Industry News
- October 2022 - Pfizer Inc. announced the completion of its acquisition of biopharmaceutical firm Global Blood Therapeutics, Inc. This acquisition would bring GBT’s leading pipeline and portfolio of SCD treatments to Pfizer in order to develop and deliver life-changing products that cater to the critical needs of underserved patient communities.
Partial Table of Contents (ToC) of the report:
Chapter 3 Sickle Cell disease Treatment Industry Insights
3.1 Industry landscape, 2018 – 2032 (USD Million)
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of sickle cell disease
3.2.1.2 Increasing R&D activities in drug development for sickle cell disease
3.2.1.3 Increasing healthcare expenditure and government initiatives
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost associated with the treatment
3.2.2.2 Side effects associated with sickle cell disease treatment drugs
3.3 Growth potential analysis
3.3.1 By treatment modality
3.3.2 By disease type
3.3.3 By end-user
3.4 COVID-19 impact analysis
3.5 Clinical trial analysis
3.6 Regulatory landscape
3.7 Porter’s analysis
3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Global company market share analysis, 2022
4.4 Competitive positioning matrix, 2022
4.5 Strategic dashboard, 2022
Browse Our Reports Store - GMIPulse @ https://www.gminsights.com/gmipulse
About Global Market Insights
Global Market Insights Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider, offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy, and biotechnology.
